AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Prolia (Amgen) (prolia.com)
This site contains almost no BS. It is a data-heavy regulatory asset where every marketing claim is physically tethered to a clinical footnote or a safety warning. It prioritizes scientific substance over emotional signal to a degree rarely seen outside of the healthcare sector.
Implement Organization and MedicalWebPage schema to bridge the technical authority gap. Include specific ClinicalTrials.gov identifiers (NCT numbers) directly next to the study result mentions to provide a direct verification path for healthcare providers. Convert the ‘See the Evidence’ call-to-action into a direct PDF link to the peer-reviewed publications cited in the BMD studies. Add a specific ‘Last Reviewed by Medical Affairs’ date to the bottom of data-heavy sections to ensure temporal credibility as the 2024-2025 data ages.
Information density is remarkably high, dominated by forensic medical data rather than marketing fluff. Substantiated claims include specific fracture risk percentages like ‘7.2% compared to 2.3%’ in a 3-year study of 7,393 patients. While headings like ‘Real patients Real voices’ lean into narrative marketing, they are immediately anchored by specific treatment start dates (e.g., ‘since 2015′) and global patient estimates of ’26 million women’. The ratio of power words to nouns is low, with the text favoring clinical terms like ‘hypocalcemia’ and ‘osteonecrosis’ over generic excellence claims.
When your heading hierarchy collapses, AI cannot determine where one idea ends and the next begins. Run a Semantic HTML Machine Readability Audit to see how your structure is actually chunked by LLMs.
There is zero detectable semantic drift between the homepage promise and the sub-page evidence. The homepage H5 establishes a signal of ‘strengthen and protect,’ which is rigorously defended on the ‘Proven Results’ page through head-to-head bone mineral density (BMD) studies against alendronate. The ‘Paying for Prolia’ sub-page provides granular logistics for Medicare Part B and D, including specific pharmacy networks (Accredo, CVS Specialty), fulfilling the ‘access’ promise made in the navigation hierarchy. The messaging remains focused on the primary indication of postmenopausal osteoporosis throughout the entire journey.
Move beyond vague agency reporting and visualize your surgical implementation plan. Order an Executive SEO Strategy and stop relying on superficial keyword tracking.
The site avoids trust theatre by prioritizing regulatory transparency over social proof. Review counts are 0 because the site correctly uses ‘Real Voices’ testimonials as anecdotal patient experience rather than verified star ratings, which would be inappropriate for a prescription biologic. Performance claims are substantiated by references to IQVIA prescription data and MMIT coverage data snapshots from early 2025. The presence of the FDA MedWatch reporting number (1-800-FDA-1088) acts as a high-authority proof path that neutralizes any ‘marketing’ feel.
Proof density is exceptional, with 8+ instances of hard evidence across the four pages, including study patient counts (7,393), study duration (3 years), and real-world evidence scale (500,000 women). The site effectively uses footnotes to source coverage data as of January 2025 and prescription data through June 2024. Vague assertions are nearly non-existent; even patient testimonials are caveated with ‘Individual results may vary’ and specific dates of treatment initiation.
To evaluate URL identity stability and multilingual coherence, review the Yoast Identity Stability audit. View the Yoast Identity Stability Audit for a practical example of canonical alignment and language layer integrity.
The site matches several industry clichés such as ‘clinically proven’ and ‘real-world study,’ but these are exemptions as they describe specific technical datasets (e.g., the 500,000 women study). The value proposition of ‘1 shot every 6 months’ is a unique differentiator compared to daily or weekly oral bisphosphonates, reducing its commodity score. The template language is dictated by legal necessity (Approved Uses, Medication Guide) rather than lazy design. The only fingerprint penalty comes from the standard ‘Doctor Discussion Guide’ and ‘Patient Resources’ blocks which are common across all pharmaceutical brand sites.
The primary authority gap is technical: the schema_json is null across the crawled pages, representing a missed opportunity for Organization and Drug schema implementation. While the brand Amgen is a global authority, the site lacks Person schema for researchers or medical directors, relying instead on the corporate entity for credibility. However, the presence of specific patent-related data and IQVIA-backed syringe counts provides a verification footprint that compensates for the lack of structured data. The expert claims are verified by the mandatory full Prescribing Information link.
There is no disconnect between claims and evidence. The site claims Prolia is ‘proven to help strengthen bones’ and immediately follows this with BMD data from head-to-head trials against common treatments like Fosamax. It does not promise a ‘cure’ or ‘revolutionary’ results without attaching those words to specific 3-year clinical outcomes. The performance claims are limited to the ‘high risk for fracture’ population, demonstrating a restrained, scientifically defensible marketing tone.
Medical Devices, Pharma & Biotech BS: Prolia (Amgen) (prolia.com)
The site perfectly aligns with the Pharma and Biotech industry category. It adheres strictly to regulatory communication standards, balancing therapeutic claims with the mandatory Important Safety Information (ISI) and detailed prescribing guidelines.
When your canonical, redirect, and final URL disagree, the model treats each version as a separate entity. Study the Canonical Integrity Framework Guide and see why stable identity is the prerequisite for AI driven retrieval.
“The low score of 17 is driven primarily by the high Body Substance Ratio and the absence of semantic drift. Minor points were lost in the Identity pillar due to the lack of structured schema and in the Information Density pillar due to the repetitive nature of the '1 shot every 6 months' value proposition. The site is a benchmark for high-substance, low-fluff pharmaceutical communication.”
Analysis Disclosure & Source Attribution
Snapshot Date: June 19, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at Prolia (Amgen) to view the most current version of their content and see directly what the company offers.